ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0413

Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort

Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada

Meeting: ACR Convergence 2021

Keywords: interstitial lung disease, risk factors, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials in anti-fibrotic medications have shown promise in reducing rates of lung function decline in patients with SSc-ILD. Identifying SSc-ILD development and initiating therapy early is essential to optimizing therapeutic benefit. We aimed to identify predictors of SSc-ILD and compared early (< 5 years from SSc diagnosis) versus late onset to aid in optimizing targeted screening for SSc-ILD.

Methods: We analyzed data from the Canadian Scleroderma Research Group (CSRG) patient registry. Patients ≥18 years with follow-up until July 2019 were included. Logistic regression modelling by ordinary least squares and forward stepwise regression were run to identify patient factors associated with SSc-ILD development as well as its early onset (< 5 years from SSc diagnosis). Factors associated with incident ILD were determined as were factors associated with early versus late onset using all patients who developed SSc-ILD during follow-up. Bonferroni correction was utilized to limit Type 1 errors.

Results: Of 1695 patients followed between August 2004 and July 2019, 417 developed SSc-ILD; 227 were incident diagnoses after registry entry. Patients were predominantly middle-aged Caucasian females. General risk factors for ILD including family history, environmental exposures and smoking histories were overall low prevalence in the population and similar between those that did and did not develop SSc-ILD.

Logistic regression identified 12 patient factors associated with increased or decreased odds of developing ILD independent of age and sex (Table 1). Forward stepwise selection revealed 6 significant predictors of SSc-ILD development (Figure 1). Age at SSc diagnosis was the only predictor of early-onset SSc-ILD with older age at SSc diagnosis being associated with increased odds of SSc-ILD onset before 5 years (Table 2).

Conclusion: In a large Canadian cohort we identified 6 factors significantly associated with risk of developing SSc-ILD: baseline pulmonary function (with higher baseline DLCO and FVC reducing risk), antibody status (ATA positivity increasing risk, ACA positivity decreasing risk), elevated hemoglobin and older age at Raynaud’s onset. Only older age at SSc diagnosis was predictive of early-onset SSc-ILD .


Disclosures: J. Kapralik, None; R. Morton, None; M. Farooqi, None; K. Beattie, None; N. Hambly, None; M. Larche, Adiga Life Science Inc, 10.

To cite this abstract in AMA style:

Kapralik J, Morton R, Farooqi M, Beattie K, Hambly N, Larche M. Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/predictors-of-ild-development-and-timing-of-onset-in-systemic-sclerosis-a-canadian-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-ild-development-and-timing-of-onset-in-systemic-sclerosis-a-canadian-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology